Active	Status	Sponsor type	Region	Phase	Filter
1 Active 15 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
PARK, sung-woo
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF	Terminated	3	372	Europe, US, RoW	Pamrevlumab, FG-3019, Placebo	FibroGen	Idiopathic Pulmonary Fibrosis	09/23	09/23